DBV Technologies S.A. (DBV.F)

1,1780 +0,0100 (+0,86%) Börsenschluss: 03:08PM CEST

DBV Technologies S.A.

177-181 Avenue Pierre Brossolette
Montrouge 92120
France
33 1 55 42 78 78
https://www.dbv-technologies.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 104

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Daniel Tassé	CEO & Director	1,24M	N/A	1960
Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C.	Chief Operations Officer	N/A	N/A	N/A
Ms. Michele F. Robertson	Chief Legal Officer	N/A	N/A	N/A
Ms. Caroline Daniere	Chief Human Resources Officer & Chief of Staff	N/A	N/A	1975
Dr. Wence Agbotounou	Chief Clinical Trial Officer & Senior VP	N/A	N/A	N/A
Mr. Edward P. Jordan M.B.A.	Senior Vice President of Commercial Operations North America	N/A	N/A	1968
Alan Kerr	Senior VP & Head of Global Regulatory Affairs	N/A	N/A	N/A
Mr. Pascal Wotling	Chief External Manufacturing & Supply Chain Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Corporate Governance

DBV Technologies S.A.s ISS Governance QualityScore, Stand 29. April 2024, lautet 10. Die grundlegenden Scores sind Audit: 6, Vorstand: 9, Shareholderrechte: 1, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.